Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | HTR2A | P28223 | 7/20 | 0.55 |
| ▸ | HTR7 | P34969 | 6/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440200 | 0.85 | DRD2 (0.50) | DRD2HTR2AHTR7HTR1AADRA1A | |
| SCHEMBL10036403 | 0.84 | DRD2 (0.49) | DRD2HTR2AHTR7HTR1AADRA1A | |
| SCHEMBL16440177 | 0.84 | DRD2 (0.50) | DRD2HTR2AHTR7HTR1AADRA1A | |
| SCHEMBL8828454 | 0.83 | DRD2 (0.56) | DRD2HTR2AHTR7HTR1AADRA1A | |
| SCHEMBL16437254 | 0.82 | DRD2 (0.49) | DRD2HTR7HTR1AADRA1ADRD3 | |
| SCHEMBL12082468 | 0.82 | DRD2 (0.62) | DRD2HTR2AHTR7HTR1AADRA1A | |
| SCHEMBL28710426 | 0.81 | ALDH1A1 (0.67) | DRD2HTR7HTR1AADRA1ADRD3 | |
| SCHEMBL20306332 | 0.79 | DRD2 (0.47) | DRD2HTR1AADRA1ADRD3DRD4 | |
| SCHEMBL25797045 | 0.79 | ALDH1A1 (0.57) | DRD2HTR2AHTR1AADRA1AMEN1 | |
| SCHEMBL17665083 | 0.79 | KMT2A (0.50) | DRD2HTR2AHTR7HTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | DRD2 3499/4885HTR2A 2789/4885HTR7 2822/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | DRD2 3702/4885HTR2A 2886/4885HTR7 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.